Progentec aiSLE DX Flare Risk Index
Progentec announced the launch of a novel blood test to determine the likelihood of a patient with systemic lupus erythematosus experiencing a flareup in the next 12 weeks. The aiSLE DX Flare Risk Index uses blood-based biomarkers that are altered before flare symptoms occur and uses the Ella platform.
A blood test measures 11 soluble mediators, including cytokines and chemokines, and a machine learning algorithm creates the score from the analytes. Originally, 52 immune mediators were examined in study participants for baseline and follow-up plasma levels, but continued studies during test development decreased the number of informative mediators to 11.
According to the company, lupus patients with a positive index score are five times more likely to experience a flare than a patient with a negative score.